
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.780 | 1.050 | 0.270 |
Shares | 99.210 | 99.210 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 16.823 | 19.721 |
Price to Book | 3.473 | 3.900 |
Price to Sales | 2.810 | 2.233 |
Price to Cash Flow | 13.303 | 14.997 |
Dividend Yield | 1.213 | 1.495 |
5 Years Earnings Growth | 7.510 | 9.862 |
Number of long holdings: 64
Number of short holdings: 5
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Medincell | FR0004065605 | 6.70 | 15.98 | +0.44% | |
Eli Lilly | US5324571083 | 4.31 | 625.65 | -2.37% | |
Boston Scientific | US1011371077 | 3.65 | 103.14 | +0.17% | |
AstraZeneca | GB0009895292 | 3.51 | 10,922.0 | -0.26% | |
AbbVie | US00287Y1091 | 3.45 | 198.05 | -0.41% | |
Fresenius SE | DE0005785604 | 3.16 | 43.7400 | +3.45% | |
Novo Nordisk B | DK0062498333 | 2.98 | 323.1 | +4.60% | |
RaySearch Labs B | SE0000135485 | 2.78 | 300.50 | -1.31% | |
Thermo Fisher Scientific | US8835561023 | 2.56 | 460.72 | +1.32% | |
Lantheus Holdings Inc | US5165441032 | 2.52 | 57.20 | +4.27% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Pluvalca Disruptive Opportunities A | 100.89M | 1.13 | -3.88 | - | ||
Pluvalca Initiatives PME A | 84.72M | 24.44 | 0.69 | 7.01 | ||
Pluvalca Allcaps A | 51.64M | 9.54 | 6.67 | 4.84 | ||
Pluvalca France Small Caps A | 48.78M | 16.88 | 2.23 | 4.17 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review